Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first …
K Kashiwabara, S Fujii, S Tsumura… - Journal of Cancer …, 2021 - Springer
Background The survival benefit of first-line epidermal growth factor receptor-tyrosine kinase
inhibitor (EGFR-TKI) therapy in super-elderly patients with advanced non-small cell lung …
inhibitor (EGFR-TKI) therapy in super-elderly patients with advanced non-small cell lung …
First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: Multicenter phase II trial (NEJ 003 …
Y Minegishi, M Maemondo, S Okinaga… - Journal of Clinical …, 2010 - ascopubs.org
7561 Background: First line treatment by gefitinib for NSCLC patients with EGFR mutations
has been validated by us (NEJ 002 Study) and WJTOG3405. In these studies, patients with …
has been validated by us (NEJ 002 Study) and WJTOG3405. In these studies, patients with …
First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations
Purpose The efficacy of gefitinib [an epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor] in elderly patients with non-small cell lung cancer (NSCLC) and EGFR …
kinase inhibitor] in elderly patients with non-small cell lung cancer (NSCLC) and EGFR …
Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis
H Uruga, K Kishi, T Fujii, Y Beika, T Enomoto… - Internal …, 2010 - jstage.jst.go.jp
Internal Medicine Vol.49 Page 1 103 □ ORIGINAL ARTICLE □ Efficacy of Gefitinib for Elderly
Patients with Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor …
Patients with Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor …
Survival analysis for older patients with epidermal growth factor receptor mutation‐positive advanced non‐small cell lung cancer after progression of first‐line gefitinib
X Nie, P Zhang, G Cheng, XN Wu… - Asia‐Pacific Journal of …, 2022 - Wiley Online Library
Aim Currently, little studies focus on treatment strategies and survival after progression of
gefitinib in older patients with epidermal growth factor receptor) EGFR (mutant advanced …
gefitinib in older patients with epidermal growth factor receptor) EGFR (mutant advanced …
[HTML][HTML] First-line gefitinib in patients aged 75 or older with advanced non–small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study
M Maemondo, Y Minegishi, A Inoue… - Journal of Thoracic …, 2012 - Elsevier
Introduction: Recent studies have demonstrated that first-line treatment with gefitinib, an
epidermal growth factor receptor (EFGR)–targeted tyrosine kinase inhibitor, is significantly …
epidermal growth factor receptor (EFGR)–targeted tyrosine kinase inhibitor, is significantly …
First-line gefitinib for elderly patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations: A combined analysis of NEJ studies.
S Narumi, A Inoue, N Morikawa, Y Minegishi… - 2012 - ascopubs.org
7563 Background: The first-line treatment with gefitinib has been established as a standard
of care for advanced NSCLC patients with EGFR mutation by previous studies including …
of care for advanced NSCLC patients with EGFR mutation by previous studies including …
First-line gefitinib for elderly patients harboring EGFR mutations.
K Asami, T Koizumi, S Amejima, A Morikawa… - Journal of Clinical …, 2010 - ascopubs.org
e18094 Background: Potential treatment strategies for elderly patients (pts) with advanced
non-small cell lung cancer (NSCLC) have not been well investigated. Gefitinib has …
non-small cell lung cancer (NSCLC) have not been well investigated. Gefitinib has …
Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective …
K Tateishi, T Ichiyama, K Hirai, T Agatsuma, S Koyama… - Medical oncology, 2013 - Springer
The clinical efficacy and outcomes of gefitinib therapy as a first-line treatment for elderly
patients with non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor …
patients with non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor …
First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901
K Takahashi, H Saito, Y Hasegawa, M Ando… - Cancer chemotherapy …, 2014 - Springer
Background The population of elderly patients with lung cancer is increasing worldwide.
Although first-line gefitinib is one of the standard treatments for advanced non-small cell …
Although first-line gefitinib is one of the standard treatments for advanced non-small cell …
相关搜索
- gefitinib therapy growth factor
- receptor mutation growth factor
- lung cancer growth factor
- gefitinib therapy receptor mutations
- receptor tyrosine lung cancer
- lung cancer kinase inhibitors
- older patients growth factor
- survival analysis growth factor
- kinase inhibitors growth factor
- lung cancer retrospective analysis
- gefitinib therapy multicenter phase
- receptor mutation older patients
- receptor mutation survival analysis
- egfr mutations elderly patients
- receptor tyrosine kinase inhibitors
- egfr mutations gefitinib treatment